MTA1 (K182) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
MTA1 (K182) Peptide Applications :
Blocking Background :
MTA1 (metastasis-associated protein 1) is a component of the NURD (for nucleosome remodeling and histone deacetylation) complex, which is associated with ATP-dependent chromatin-remodeling and histone deacetylase activity. MTA1 functions in conjunction with other components of NURD to mediate transcriptional repression as it facilitates the association of repressor molecules with the chromatin. Structurally, MTA1 contains a single SH3-binding motif and a zinc finger domain, along with a region similar to the corepressor protein N-Cor. MTA1 is normally expressed at low levels in various tissues and is more highly expressed in testis. Overexpression of MTA1 correlates with tumor invasion and metastasis in various carcinomas including colorectal, gastrointestinal and breast carcinomas. Elevated MTA1 levels in these tumors appears to enhance the metastases to lymph nodes, increase mammary cell motility and potentiate growth, and it may, therefore, be an indicator for assessing the potential malignancies of various tumors. A similar protein, MTA1-L1 (MTA1-like protein 1), shares more than 55% sequence homology with MTA1 and is ubiquitously expressed. Alternative Name :
MSI2; FLJ36569; MGC3245; MSI2H; MUSASHI-2 Swiss-Prot :
Q13330 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide MTA1 (K182). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2045 MTA1 (K182) pAb.
MTA1 (K182) Peptide Applications :
Blocking Background :
MTA1 (metastasis-associated protein 1) is a component of the NURD (for nucleosome remodeling and histone deacetylation) complex, which is associated with ATP-dependent chromatin-remodeling and histone deacetylase activity. MTA1 functions in conjunction with other components of NURD to mediate transcriptional repression as it facilitates the association of repressor molecules with the chromatin. Structurally, MTA1 contains a single SH3-binding motif and a zinc finger domain, along with a region similar to the corepressor protein N-Cor. MTA1 is normally expressed at low levels in various tissues and is more highly expressed in testis. Overexpression of MTA1 correlates with tumor invasion and metastasis in various carcinomas including colorectal, gastrointestinal and breast carcinomas. Elevated MTA1 levels in these tumors appears to enhance the metastases to lymph nodes, increase mammary cell motility and potentiate growth, and it may, therefore, be an indicator for assessing the potential malignancies of various tumors. A similar protein, MTA1-L1 (MTA1-like protein 1), shares more than 55% sequence homology with MTA1 and is ubiquitously expressed. Alternative Name :
MSI2; FLJ36569; MGC3245; MSI2H; MUSASHI-2 Swiss-Prot :
Q13330 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide MTA1 (K182). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2045 MTA1 (K182) pAb.
Blocking peptide available as BS2045PP